Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 17/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 16/20 | 0.43 |
| ▸ | RXRA | P19793 | 6/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15242947 | 0.92 | NR1H3 (0.42) | NR1H3NR1H2RXRAPIK3CA | |
| SCHEMBL16455636 | 0.88 | NR1H3 (0.46) | NR1H3NR1H2RXRAPIK3CA | |
| SCHEMBL16455299 | 0.85 | NR1H2 (0.43) | NR1H3NR1H2RXRAS1PR1 | |
| SCHEMBL16587434 | 0.85 | NR1H2 (0.48) | NR1H3NR1H2RXRAPIK3CAS1PR1 | |
| SCHEMBL19633179 | 0.84 | NR1H2 (0.46) | NR1H3NR1H2RXRAPIK3CA | |
| SCHEMBL16455635 | 0.83 | NR1H2 (0.43) | NR1H3NR1H2RXRA | |
| SCHEMBL16455393 | 0.83 | NR1H2 (0.44) | NR1H3NR1H2RXRAPIK3CA | |
| SCHEMBL19633201 | 0.82 | HSP90AA1 (0.33) | NR1H3NR1H2RXRA | |
| SCHEMBL15242879 | 0.81 | NR1H2 (0.48) | NR1H3NR1H2RXRAPIK3CA | |
| SCHEMBL15242752 | 0.81 | NR1H2 (0.45) | NR1H3NR1H2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8987318-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H3 2/4885NR1H2 1/4885RXRA 3/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H3 2/4885NR1H2 1/4885RXRA 3/4885 |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRA | NR1H3 2/4885NR1H2 1/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.